How much cash does Corvus Pharmaceuticals generate?

Corvus Pharmaceuticals (CRVS) generated -$34.9M in operating cash flow over the trailing twelve months.

What is Corvus Pharmaceuticals's free cash flow?

After $229.0K of capital expenditures, Corvus Pharmaceuticals's free cash flow was -$35.1M over the trailing twelve months, down 45.7% year over year.

Where does Corvus Pharmaceuticals's cash flow data come from?

Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Corvus Pharmaceuticals CRVS Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$44.17M-189%	-$15.28M-1.4%	-$15.08M+66.6%	-$45.14M-9.0%	-$41.4M+33.5%
Depreciation and amortization	$112K+6.7%	$105K+6.1%	$99K+7.6%	$92K+9.5%	$84K-1.2%
Stock-based compensation	$6.73M+26.2%	$5.33M+16.7%	$4.57M+12.7%	$4.05M+13.7%	$3.57M+18.7%
Gain (loss) on sale of assets	——	——	——	——	——
Change in accounts payable	——	——	$101K-94.8%	$1.92M+739%	-$301K-128%
Change in accrued liabilities	$3.11M+12.8%	$2.76M+83.3%	$1.51M+112%	$709K+455%	-$200K+18.4%
Change in other assets	-$344K-1.8%	-$338K-153%	$643K+48.2%	$434K+88.7%	$230K+721%
Net gains (losses) on investments	-$2.02M-3.1%	-$1.96M+42.8%	-$3.43M+9.5%	-$3.78M+4.7%	-$3.97M-24.2%
Change in operating lease liabilities	-$319K-72.4%	-$185K—	——	——	——
Change in other current assets	$1.09M+389%	$223K-62.8%	$600K+20.7%	$497K—	——
Net cash from operating activities	-$34.91M-6.4%	-$32.8M-2.3%	-$32.07M-11.3%	-$28.83M-1.0%	-$28.53M-12.2%
Capital expenditures	$229K+31.6%	$174K—	——	——	——
Purchases of investments	$245.78M+168%	$91.75M-7.0%	$98.69M+14.3%	$86.38M+18.0%	$73.2M+4.4%
Proceeds from maturities/sales of investments	$89.12M+5.9%	$84.13M+13.6%	$74.08M+22.5%	$60.49M+21.0%	$50M+17.3%
Proceeds from sale of property, plant and equipment	——	——	——	——	——
Net cash from investing activities	——	——	-$24.76M+4.9%	-$26.03M-12.0%	-$23.23M+15.5%
Proceeds from issuance of common stock	$189.81M+27,650%	$684K-85.6%	$4.77M-44.0%	$8.51M-32.4%	$12.58M-23.3%
Net cash from financing activities	$226.9M+523%	$36.43M-33.8%	$55.02M+0.6%	$54.71M—	——
Net increase (decrease) in cash	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$1.07M-20.4%	$1.35M+1.4%	$1.33M-4.7%	$1.39M+8.6%	$1.28M+12.3%
Equity in earnings (losses) of equity method investees	-$2.02M-3.1%	-$1.96M+42.8%	-$3.43M+9.5%	-$3.78M+4.7%	-$3.97M-24.2%
Accrued expenses and other liabilities	$3.11M+12.8%	$2.76M+83.3%	$1.51M+112%	$709K+455%	-$200K+18.4%
Operating lease liabilities	-$319K-72.4%	-$185K—	——	——	——
Increase (Decrease) in Other Current Assets	$1.09M+389%	$223K-62.8%	$600K+20.7%	$497K—	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	$503K-68.3%
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$89.12M+5.9%	$84.13M+13.6%	$74.08M+22.5%	$60.49M+21.0%	$50M+17.3%
Proceeds from disposals of property, plant and equipment	——	——	——	——	——
Fair Value Adjustment Of Warrants	——	——	——	$8.05M-2.4%	$8.25M-75.3%
Increase Decrease In Operating Lease Liability	-$319K-72.4%	-$185K—	——	——	——
Proceeds From Pre Funded Warrants Financing Activities	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Issuances of common stock from employee benefit plans receivable	——	$1.77M-62.2%	$4.68M-38.3%	$7.59M-27.7%	$10.49M-21.7%
Offering Costs Accrued And Charged To Additional Paid In Capital	——	——	——	——	——
Free cash flow	-$35.14M-6.6%	-$32.97M—	——	——	——
Free cash flow	-$35.14M-6.6%	-$32.97M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Corvus Pharmaceuticals generate?: Corvus Pharmaceuticals (CRVS) generated -$34.9M in operating cash flow over the trailing twelve months.
What is Corvus Pharmaceuticals's free cash flow?: After $229.0K of capital expenditures, Corvus Pharmaceuticals's free cash flow was -$35.1M over the trailing twelve months, down 45.7% year over year.
Where does Corvus Pharmaceuticals's cash flow data come from?: Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.